Drugs affecting coagulation

For more than half a century, heparin and vitamin K antagonists have defined anticoagulant therapy in both the short-term and long-term management of thrombotic diseases. However, the limitations of these traditional anticoagulants have prompted the development of new drugs. In the past 15 years new...

Full description

Saved in:
Bibliographic Details
Published inAnaesthesia and intensive care medicine Vol. 19; no. 12; pp. 656 - 663
Main Authors Appadu, Balraj, Barber, Katrina
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.12.2018
Subjects
ADP receptor antagonists
dabigatran
fondaparinux
glycoprotein IIb/IIIa antagonists
heparin
rivaroxaban
warfarin
heparin
fondaparinux
dabigatran
rivaroxaban
ADP receptor antagonists
glycoprotein IIb/IIIa antagonists
warfarin
Online AccessGet full text

Cover

More Information
Summary:For more than half a century, heparin and vitamin K antagonists have defined anticoagulant therapy in both the short-term and long-term management of thrombotic diseases. However, the limitations of these traditional anticoagulants have prompted the development of new drugs. In the past 15 years new agents with improved safety profile and greater ease of use that target almost every step of the coagulation cascade have been developed. These include factor Xa inhibitors and direct thrombin inhibitors. The mechanism of action of these new anticoagulants and also the ‘older’ agents are reviewed in this article.
ISSN:1472-0299
1878-7584
DOI:10.1016/j.mpaic.2018.09.002